Aquestive Therapeutics, Inc. (AQST) FinancialsAQSTAquestive Therapeutics, Inc.

Evaluating the bottom line, Aquestive Therapeutics, Inc. maintains a gross margin of 70.93%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -59.51%, while the net margin is -165.45%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively AQST converts its operational activities into shareholder value.

In the context of the broader market, AQST competes directly with industry leaders such as EOLS and ENTX. With a market capitalization of $474.43M, it holds a significant position in the sector. When comparing efficiency, AQST's gross margin of 70.93% stands against EOLS's 66.19% and ENTX's N/A. Such benchmarking helps identify whether Aquestive Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

In Q2 2026, revenue was $13.8 million, a 38% year-over-year increase, but the net loss was $22.9 million, highlighting financial challenges. Gross margin improved to 70.93%, indicating better cost management.